{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:38Z","timestamp":1787009918909,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>To determine whether angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors are associated with improved outcomes in hospitalized patients with COVID-19 according to sex and to report sex-related differences in renin-angiotensin system (RAS) components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>\n                      Prospective observational cohort study comparing the effects of ARB or ACE inhibitors versus no ARBs or ACE inhibitors in males versus females. Severe acute respiratory syndrome coronavirus 2 downregulates ACE-2, potentially increasing angiotensin II (a pro-inflammatory vasoconstrictor). Sex-based differences in RAS dysregulation may explain sex-based differences in responses to ARBs because the\n                      <jats:italic toggle=\"yes\">ACE2<\/jats:italic>\n                      gene is on the X chromosome. We recorded baseline characteristics, comorbidities, prehospital ARBs or ACE inhibitor treatment, use of organ support and mortality, and measured RAS components at admission and days 2, 4, 7, and 14 in a subgroup (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 46), recorded\n                      <jats:sc>d<\/jats:sc>\n                      -dimer (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 967), comparing males with females.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>ARBs CORONA I is a multicenter Canadian observational cohort of patients hospitalized with acute COVID-19. This analysis includes patients admitted to 10 large urban hospitals across the four most populated provinces.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS:<\/jats:title>\n                    <jats:p>One-thousand six-hundred eighty-six patients with polymerase chain reaction-confirmed COVID-19 (February 2020 to March 2021) for acute COVID-19 illness were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTIONS:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n                    <jats:p>\n                      Males on ARBs before admission had decreased use of ventilation (adjusted odds ratio [aOR] = 0.52;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.007) and vasopressors (aOR = 0.55;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.011) compared with males not on ARBs or ACE inhibitors. No significant effects were observed in females for these outcomes. The test for interaction was significant for use of ventilation (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.006) and vasopressors (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.044) indicating significantly different responses to ARBs according to sex. Males had significantly higher plasma ACE-1 at baseline and angiotensin II at day 7 and 14 than females.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>ARBs use was associated with less ventilation and vasopressors in males but not females. Sex-based differences in RAS dysregulation may contribute to sex-based differences in outcomes and responses to ARBs in COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ccm.0000000000005589","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T05:00:22Z","timestamp":1653368422000},"page":"1306-1317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*"],"prefix":"10.1097","volume":"50","author":[{"given":"Genevieve L. Y.","family":"Rocheleau","sequence":"first","affiliation":[{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Lee","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Science (CHEOS), St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassene","family":"Mohammed","sequence":"additional","affiliation":[{"name":"University of Victoria, Genome BC Proteomics Centre, Victoria, BC, Canada."},{"name":"Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goodlett","sequence":"additional","affiliation":[{"name":"University of Victoria, Genome BC Proteomics Centre, Victoria, BC, Canada."},{"name":"Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada."},{"name":"International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Burns","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Center, McGill\u2019s Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tran","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sweet","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Vancouver General Hospital, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Surgery, St. Michael\u2019s Hospital, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"Slutsky","sequence":"additional","affiliation":[{"name":"Department of Surgery, St. Michael\u2019s Hospital, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Murthy","sequence":"additional","affiliation":[{"name":"British Columbia Children\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Science (CHEOS), St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Patrick","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control (BCCDC), and School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Du","sequence":"additional","affiliation":[{"name":"Medical ICU, Peking Union Medical College Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Center, McGill\u2019s Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."},{"name":"Division of Critical Care Medicine, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Walley","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."},{"name":"Division of Critical Care Medicine, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Lamontagne","sequence":"additional","affiliation":[{"name":"University of Sherbrooke, Sherbrooke, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fowler","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent W.","family":"Winston","sequence":"additional","affiliation":[{"name":"Departments of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Haljan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surrey Memorial Hospital, Surrey, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Vinh","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Center, McGill\u2019s Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McGeer","sequence":"additional","affiliation":[{"name":"Mt. Sinai Hospital and University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maslove","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kingston General Hospital and Queen\u2019s University, Kingston, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Perez","family":"Patrigeon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kingston General Hospital and Queen\u2019s University, Kingston, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Mann","sequence":"additional","affiliation":[{"name":"Black Tusk Research Group Inc., Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Donohoe","sequence":"additional","affiliation":[{"name":"Black Tusk Research Group Inc., Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Black Tusk Research Group Inc., Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Russell","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."},{"name":"Division of Critical Care Medicine, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for ARBs CORONA I Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure.","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-008-0336-0","article-title":"Update on tissue renin-angiotensin systems.","volume":"86","author":"Bader","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","article-title":"ACE2: From vasopeptidase to SARS virus receptor.","volume":"25","author":"Turner","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11427-015-4814-7","article-title":"Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse.","volume":"58","author":"Yan","year":"2015","journal-title":"Sci China Life Sci"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1038\/srep07027","article-title":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.","volume":"4","author":"Yang","year":"2014","journal-title":"Sci Rep"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1038\/ncomms4595","article-title":"Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients.","volume":"5","author":"Huang","year":"2014","journal-title":"Nat Commun"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ajh\/hpaa169","article-title":"Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19.","volume":"34","author":"Rieder","year":"2021","journal-title":"Am J Hypertens"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"625732","DOI":"10.3389\/fimmu.2021.625732","article-title":"Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients.","volume":"12","author":"Osman","year":"2021","journal-title":"Front Immunol"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-20-1445","article-title":"Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.","volume":"184","author":"Kutz","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1097\/CCM.0000000000004967","article-title":"Efficacy of serum angiotensin II levels in prognosis of patients with coronavirus disease 2019.","volume":"49","author":"Ozkan","year":"2021","journal-title":"Crit Care Med"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/0886022X.2018.1533867","article-title":"Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis.","volume":"40","author":"Ougaard","year":"2018","journal-title":"Ren Fail"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s10620-019-5474-4","article-title":"Impact of angiotensin II signaling blockade on clinical outcomes in patients with inflammatory bowel disease.","volume":"64","author":"Jacobs","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3122\/jabfm.2020.01.190134","article-title":"Anti-hypertensive medication combinations in the United States.","volume":"33","author":"Johansen","year":"2020","journal-title":"J Am Board Fam Med"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States.","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pmedr.2016.01.005","article-title":"Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey.","volume":"3","author":"Ibrahim","year":"2016","journal-title":"Prev Med Rep"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of COVID-19 patients: An open multicenter randomized clinical trial.","volume":"37","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: A prospective, randomised, open-label trial.","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13293-020-00304-9","article-title":"Impact of sex and gender on COVID-19 outcomes in Europe.","volume":"11","author":"Gebhard","year":"2020","journal-title":"Biol Sex Differ"},{"key":"R23-20250502","article-title":"An overview of sex hormones in relation to SARS-CoV-2 infection.","author":"Naz","year":"2021","journal-title":"Future Virol"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.mayocp.2020.07.024","article-title":"COVID-19 and sex differences: Mechanisms and biomarkers.","volume":"95","author":"Haitao","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function.","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.2174\/0929867324666170414162841","article-title":"Circulating ACE2 in cardiovascular and kidney diseases.","volume":"24","author":"Anguiano","year":"2017","journal-title":"Curr Med Chem"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","article-title":"Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications.","volume":"30","author":"Soro-Paavonen","year":"2012","journal-title":"J Hypertens"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13293-017-0128-8","article-title":"Sex differences in the aging pattern of renin-angiotensin system serum peptidases.","volume":"8","author":"Fern\u00e1ndez-Atucha","year":"2017","journal-title":"Biol Sex Differ"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11357-020-00300-2","article-title":"Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: Implications for ACE2 as a biomarker for the severity of COVID-19.","volume":"43","author":"Fagyas","year":"2021","journal-title":"Geroscience"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research.","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/01.CCM.0000174478.70338.03","article-title":"Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge colloquium of the International Sepsis Forum.","volume":"33","author":"Marshall","year":"2005","journal-title":"Crit Care Med"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcrc.2018.05.003","article-title":"Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials.","volume":"47","author":"Russell","year":"2018","journal-title":"J Crit Care"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jama.2019.14607","article-title":"Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial.","volume":"322","author":"Laterre","year":"2019","journal-title":"JAMA"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-20250502","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.4155\/bio.15.222","article-title":"A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma.","volume":"7","author":"Percy","year":"2015","journal-title":"Bioanalysis"},{"key":"R37-20250502","article-title":"PeptideTracker: A knowledge base for collecting and storing information on protein concentrations in biological tissues.","volume":"7","author":"Mohammed","year":"2017","journal-title":"Proteomics"},{"key":"R38-20250502","doi-asserted-by":"crossref","first-page":"A17228","DOI":"10.1161\/circ.142.suppl_3.17228","article-title":"Abstract 17228: Gender differences in treatment and outcomes of patients with COVID-19 respiratory failure.","volume":"142","author":"Feroze","year":"2020","journal-title":"Circulation"},{"key":"R39-20250502","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.cjco.2021.03.001","article-title":"Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in COVID-19: Meta-analysis\/meta-regression adjusted for confounding factors.","volume":"3","author":"Lee","year":"2021","journal-title":"CJC Open"},{"key":"R40-20250502","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","article-title":"Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia.","volume":"10","author":"Geriak","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R41-20250502","doi-asserted-by":"crossref","first-page":"630209","DOI":"10.3389\/fmed.2021.630209","article-title":"An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19.","volume":"8","author":"Bengtson","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R42-20250502","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0828-282X(08)70624-X","article-title":"Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy.","volume":"24","author":"Rabi","year":"2008","journal-title":"Can J Cardiol"},{"key":"R43-20250502","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov"},{"key":"R44-20250502","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1164\/rccm.202106-1514OC","article-title":"Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19.","volume":"205","author":"Leisman","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R45-20250502","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1164\/rccm.202012-4461OC","article-title":"Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19-related acute respiratory distress syndrome.","volume":"204","author":"Gerard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R46-20250502","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/thoraxjnl-2020-215383","article-title":"Arterial and venous thromboembolism in COVID-19: A study-level meta-analysis.","volume":"76","author":"Tan","year":"2021","journal-title":"Thorax"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000005589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:10:31Z","timestamp":1746191431000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000005589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000005589","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}